AGLIETTA, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 250
EU - Europa 158
AS - Asia 33
SA - Sud America 2
Totale 443
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 247
DE - Germania 50
GB - Regno Unito 47
SE - Svezia 21
IT - Italia 15
HK - Hong Kong 9
RU - Federazione Russa 8
SG - Singapore 8
CN - Cina 6
IN - India 5
UA - Ucraina 5
FR - Francia 4
TR - Turchia 4
BE - Belgio 2
BG - Bulgaria 2
BR - Brasile 2
CA - Canada 2
LT - Lituania 2
FI - Finlandia 1
MY - Malesia 1
NO - Norvegia 1
PA - Panama 1
Totale 443
Salva come PNG Salva come JPEG
Città #
Southend 38
Fairfield 33
Houston 33
Ashburn 29
Woodbridge 24
Cambridge 19
Chandler 17
Wilmington 15
Ann Arbor 14
Nyköping 12
Seattle 12
Hong Kong 8
Dearborn 7
Singapore 6
Jacksonville 5
Modena 5
Eugene 4
Izmir 4
San Diego 3
Beijing 2
Bremen 2
Brussels 2
Florence 2
Guntur 2
Hyderabad 2
Milan 2
Nanjing 2
New York 2
Parma 2
Princeton 2
Sofia 2
Toronto 2
Albuquerque 1
As 1
Bangalore 1
Boardman 1
Central 1
Helsinki 1
Kuala Lumpur 1
London 1
Los Angeles 1
Nanning 1
Panama City 1
Philadelphia 1
Prescot 1
San Jose 1
Stanford 1
São Paulo 1
Totale 330
Salva come PNG Salva come JPEG
Nome #
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 253
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 196
Totale 449
Salva come PNG Salva come JPEG
Categoria #
all - tutte 1.422
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.422
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020112 10 4 2 9 7 16 19 11 12 7 8 7
2020/202176 10 3 7 7 7 1 13 7 3 8 5 5
2021/202251 1 12 1 5 1 4 3 5 4 1 9 5
2022/202361 9 9 5 4 11 3 4 5 4 2 3 2
2023/202433 0 2 1 3 8 1 7 4 0 1 3 3
2024/20258 8 0 0 0 0 0 0 0 0 0 0 0
Totale 449